Brokerages Set Certara, Inc. (NASDAQ:CERT) Target Price at $15.92

Certara, Inc. (NASDAQ:CERTGet Free Report) has received an average recommendation of “Hold” from the eight brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $15.92.

A number of equities research analysts recently weighed in on CERT shares. Robert W. Baird dropped their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Barclays reduced their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th.

Read Our Latest Report on Certara

Institutional Trading of Certara

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brown Brothers Harriman & Co. bought a new position in shares of Certara in the third quarter valued at about $27,292,000. Wasatch Advisors LP raised its position in shares of Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after purchasing an additional 1,651,076 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after purchasing an additional 1,128,006 shares during the period. Glenmede Trust Co. NA raised its position in shares of Certara by 78.6% in the third quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock valued at $14,123,000 after purchasing an additional 530,598 shares during the period. Finally, Kopion Asset Management LLC bought a new position in Certara during the third quarter worth about $4,457,000. 73.96% of the stock is owned by institutional investors.

Certara Price Performance

Shares of Certara stock opened at $13.89 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm’s 50-day simple moving average is $11.36 and its 200-day simple moving average is $11.86. Certara has a twelve month low of $9.41 and a twelve month high of $19.87. The firm has a market cap of $2.24 billion, a P/E ratio of -69.45, a price-to-earnings-growth ratio of 9.77 and a beta of 1.52.

Certara (NASDAQ:CERTGet Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same period last year, the firm posted $0.06 EPS. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. As a group, research analysts expect that Certara will post 0.28 EPS for the current fiscal year.

Certara Company Profile

(Get Free Report

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Recommended Stories

Analyst Recommendations for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.